# Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

> **NCT05601973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 60 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Amivantamab
- **DRUG:** Lazertinib
- **DRUG:** Zirabev

## Key facts

- **NCT ID:** NCT05601973
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-27
- **Primary completion:** 2024-08-24
- **Final completion:** 2026-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601973, "Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05601973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*